Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent rats.
Identifieur interne : 001712 ( Main/Corpus ); précédent : 001711; suivant : 001713Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent rats.
Auteurs : Emmanuelle Simon O'Brien ; Rémi Legastelois ; Hakim Houchi ; Catherine Vilpoux ; Stéphanie Alaux-Cantin ; Olivier Pierrefiche ; Etienne André ; Mickaël NaassilaSource :
- Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology [ 1740-634X ] ; 2011.
English descriptors
- KwdEn :
- Alcoholism (complications), Alcoholism (drug therapy), Alcoholism (psychology), Analysis of Variance (MeSH), Animals (MeSH), Antidepressive Agents (therapeutic use), Central Nervous System Depressants (administration & dosage), Conditioning, Operant (drug effects), Cyclopropanes (therapeutic use), Desipramine (therapeutic use), Disease Models, Animal (MeSH), Dose-Response Relationship, Drug (MeSH), Ethanol (administration & dosage), Extinction, Psychological (drug effects), Female (MeSH), Fluoxetine (therapeutic use), Locomotion (drug effects), Male (MeSH), Mice (MeSH), Mice, Inbred DBA (MeSH), Milnacipran (MeSH), Rats (MeSH), Rats, Wistar (MeSH), Self Administration (instrumentation).
- MESH :
- chemical , administration & dosage : Central Nervous System Depressants, Ethanol.
- chemical , therapeutic use : Antidepressive Agents, Cyclopropanes, Desipramine, Fluoxetine.
- complications : Alcoholism.
- drug effects : Conditioning, Operant, Extinction, Psychological, Locomotion.
- drug therapy : Alcoholism.
- instrumentation : Self Administration.
- psychology : Alcoholism.
- Analysis of Variance, Animals, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Male, Mice, Mice, Inbred DBA, Milnacipran, Rats, Rats, Wistar.
Abstract
A few clinical studies have shown that dual antidepressants (serotonergic (5-HT) and noradrenergic (NE) transporter inhibitors, SNRIs) may be effective in alcoholism treatment. We studied the effect of the dual antidepressant milnacipran on ethanol operant self-administration in acutely withdrawn ethanol-dependent and in -non-dependent Wistar rats, and used fluoxetine and desipramine to dissect both 5-HT and NE components, respectively, in the effect of milnacipran. Milnacipran was also tested for relapse after protracted abstinence and on ethanol-induced (1.0 g/kg) conditioned place preference in control rats and ethanol-induced locomotor sensitization in DBA/2J female mice. Milnacipran dose dependently (5-40 mg/kg) attenuated the increased ethanol self-administration observed during early withdrawal and was more potent in preventing reinstatement in dependent rats after protracted abstinence as compared with non-dependent rats. Desipramine and fluoxetine (10 mg/kg) blocked ethanol self-administration during early withdrawal, and recovery was delayed in dependent animals, indicating a potent effect. Ethanol self-administration was also reduced 1 day after treatment with desipramine and fluoxetine but not with milnacipran. Finally, milnacipran prevented ethanol-induced place preference in ethanol-naive rats and reduced the magnitude of ethanol-induced sensitization associated with a delayed induction in mice. Desipramine (20 mg/kg) countered sensitization development and reduced its expression at 1 week after treatment; fluoxetine (10 mg/kg) reduced sensitization expression. Thus, 5-HT and NE transmissions during sensitization expression may mediate the effect of milnacipran on sensitization induction. These results support that SNRIs may have a potential use in alcoholism treatment.
DOI: 10.1038/npp.2011.37
PubMed: 21430652
PubMed Central: PMC3096819
Links to Exploration step
pubmed:21430652Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent rats.</title><author><name sortKey="Simon O Brien, Emmanuelle" sort="Simon O Brien, Emmanuelle" uniqKey="Simon O Brien E" first="Emmanuelle" last="Simon O'Brien">Emmanuelle Simon O'Brien</name><affiliation><nlm:affiliation>Equipe Région INSERM ERI 24, Groupe de Recherche sur l'Alcool et les Pharmacodépendances, Université de Picardie Jules Verne, Faculté de Pharmacie, Amiens, France.</nlm:affiliation></affiliation></author><author><name sortKey="Legastelois, Remi" sort="Legastelois, Remi" uniqKey="Legastelois R" first="Rémi" last="Legastelois">Rémi Legastelois</name></author><author><name sortKey="Houchi, Hakim" sort="Houchi, Hakim" uniqKey="Houchi H" first="Hakim" last="Houchi">Hakim Houchi</name></author><author><name sortKey="Vilpoux, Catherine" sort="Vilpoux, Catherine" uniqKey="Vilpoux C" first="Catherine" last="Vilpoux">Catherine Vilpoux</name></author><author><name sortKey="Alaux Cantin, Stephanie" sort="Alaux Cantin, Stephanie" uniqKey="Alaux Cantin S" first="Stéphanie" last="Alaux-Cantin">Stéphanie Alaux-Cantin</name></author><author><name sortKey="Pierrefiche, Olivier" sort="Pierrefiche, Olivier" uniqKey="Pierrefiche O" first="Olivier" last="Pierrefiche">Olivier Pierrefiche</name></author><author><name sortKey="Andre, Etienne" sort="Andre, Etienne" uniqKey="Andre E" first="Etienne" last="André">Etienne André</name></author><author><name sortKey="Naassila, Mickael" sort="Naassila, Mickael" uniqKey="Naassila M" first="Mickaël" last="Naassila">Mickaël Naassila</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21430652</idno><idno type="pmid">21430652</idno><idno type="doi">10.1038/npp.2011.37</idno><idno type="pmc">PMC3096819</idno><idno type="wicri:Area/Main/Corpus">001712</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001712</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent rats.</title><author><name sortKey="Simon O Brien, Emmanuelle" sort="Simon O Brien, Emmanuelle" uniqKey="Simon O Brien E" first="Emmanuelle" last="Simon O'Brien">Emmanuelle Simon O'Brien</name><affiliation><nlm:affiliation>Equipe Région INSERM ERI 24, Groupe de Recherche sur l'Alcool et les Pharmacodépendances, Université de Picardie Jules Verne, Faculté de Pharmacie, Amiens, France.</nlm:affiliation></affiliation></author><author><name sortKey="Legastelois, Remi" sort="Legastelois, Remi" uniqKey="Legastelois R" first="Rémi" last="Legastelois">Rémi Legastelois</name></author><author><name sortKey="Houchi, Hakim" sort="Houchi, Hakim" uniqKey="Houchi H" first="Hakim" last="Houchi">Hakim Houchi</name></author><author><name sortKey="Vilpoux, Catherine" sort="Vilpoux, Catherine" uniqKey="Vilpoux C" first="Catherine" last="Vilpoux">Catherine Vilpoux</name></author><author><name sortKey="Alaux Cantin, Stephanie" sort="Alaux Cantin, Stephanie" uniqKey="Alaux Cantin S" first="Stéphanie" last="Alaux-Cantin">Stéphanie Alaux-Cantin</name></author><author><name sortKey="Pierrefiche, Olivier" sort="Pierrefiche, Olivier" uniqKey="Pierrefiche O" first="Olivier" last="Pierrefiche">Olivier Pierrefiche</name></author><author><name sortKey="Andre, Etienne" sort="Andre, Etienne" uniqKey="Andre E" first="Etienne" last="André">Etienne André</name></author><author><name sortKey="Naassila, Mickael" sort="Naassila, Mickael" uniqKey="Naassila M" first="Mickaël" last="Naassila">Mickaël Naassila</name></author></analytic><series><title level="j">Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</title><idno type="eISSN">1740-634X</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alcoholism (complications)</term><term>Alcoholism (drug therapy)</term><term>Alcoholism (psychology)</term><term>Analysis of Variance (MeSH)</term><term>Animals (MeSH)</term><term>Antidepressive Agents (therapeutic use)</term><term>Central Nervous System Depressants (administration & dosage)</term><term>Conditioning, Operant (drug effects)</term><term>Cyclopropanes (therapeutic use)</term><term>Desipramine (therapeutic use)</term><term>Disease Models, Animal (MeSH)</term><term>Dose-Response Relationship, Drug (MeSH)</term><term>Ethanol (administration & dosage)</term><term>Extinction, Psychological (drug effects)</term><term>Female (MeSH)</term><term>Fluoxetine (therapeutic use)</term><term>Locomotion (drug effects)</term><term>Male (MeSH)</term><term>Mice (MeSH)</term><term>Mice, Inbred DBA (MeSH)</term><term>Milnacipran (MeSH)</term><term>Rats (MeSH)</term><term>Rats, Wistar (MeSH)</term><term>Self Administration (instrumentation)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Central Nervous System Depressants</term><term>Ethanol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antidepressive Agents</term><term>Cyclopropanes</term><term>Desipramine</term><term>Fluoxetine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Alcoholism</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Conditioning, Operant</term><term>Extinction, Psychological</term><term>Locomotion</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Alcoholism</term></keywords><keywords scheme="MESH" qualifier="instrumentation" xml:lang="en"><term>Self Administration</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Alcoholism</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Male</term><term>Mice</term><term>Mice, Inbred DBA</term><term>Milnacipran</term><term>Rats</term><term>Rats, Wistar</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A few clinical studies have shown that dual antidepressants (serotonergic (5-HT) and noradrenergic (NE) transporter inhibitors, SNRIs) may be effective in alcoholism treatment. We studied the effect of the dual antidepressant milnacipran on ethanol operant self-administration in acutely withdrawn ethanol-dependent and in -non-dependent Wistar rats, and used fluoxetine and desipramine to dissect both 5-HT and NE components, respectively, in the effect of milnacipran. Milnacipran was also tested for relapse after protracted abstinence and on ethanol-induced (1.0 g/kg) conditioned place preference in control rats and ethanol-induced locomotor sensitization in DBA/2J female mice. Milnacipran dose dependently (5-40 mg/kg) attenuated the increased ethanol self-administration observed during early withdrawal and was more potent in preventing reinstatement in dependent rats after protracted abstinence as compared with non-dependent rats. Desipramine and fluoxetine (10 mg/kg) blocked ethanol self-administration during early withdrawal, and recovery was delayed in dependent animals, indicating a potent effect. Ethanol self-administration was also reduced 1 day after treatment with desipramine and fluoxetine but not with milnacipran. Finally, milnacipran prevented ethanol-induced place preference in ethanol-naive rats and reduced the magnitude of ethanol-induced sensitization associated with a delayed induction in mice. Desipramine (20 mg/kg) countered sensitization development and reduced its expression at 1 week after treatment; fluoxetine (10 mg/kg) reduced sensitization expression. Thus, 5-HT and NE transmissions during sensitization expression may mediate the effect of milnacipran on sensitization induction. These results support that SNRIs may have a potential use in alcoholism treatment.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21430652</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1740-634X</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>7</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</Title><ISOAbbreviation>Neuropsychopharmacology</ISOAbbreviation></Journal><ArticleTitle>Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent rats.</ArticleTitle><Pagination><MedlinePgn>1518-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/npp.2011.37</ELocationID><Abstract><AbstractText>A few clinical studies have shown that dual antidepressants (serotonergic (5-HT) and noradrenergic (NE) transporter inhibitors, SNRIs) may be effective in alcoholism treatment. We studied the effect of the dual antidepressant milnacipran on ethanol operant self-administration in acutely withdrawn ethanol-dependent and in -non-dependent Wistar rats, and used fluoxetine and desipramine to dissect both 5-HT and NE components, respectively, in the effect of milnacipran. Milnacipran was also tested for relapse after protracted abstinence and on ethanol-induced (1.0 g/kg) conditioned place preference in control rats and ethanol-induced locomotor sensitization in DBA/2J female mice. Milnacipran dose dependently (5-40 mg/kg) attenuated the increased ethanol self-administration observed during early withdrawal and was more potent in preventing reinstatement in dependent rats after protracted abstinence as compared with non-dependent rats. Desipramine and fluoxetine (10 mg/kg) blocked ethanol self-administration during early withdrawal, and recovery was delayed in dependent animals, indicating a potent effect. Ethanol self-administration was also reduced 1 day after treatment with desipramine and fluoxetine but not with milnacipran. Finally, milnacipran prevented ethanol-induced place preference in ethanol-naive rats and reduced the magnitude of ethanol-induced sensitization associated with a delayed induction in mice. Desipramine (20 mg/kg) countered sensitization development and reduced its expression at 1 week after treatment; fluoxetine (10 mg/kg) reduced sensitization expression. Thus, 5-HT and NE transmissions during sensitization expression may mediate the effect of milnacipran on sensitization induction. These results support that SNRIs may have a potential use in alcoholism treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simon O'Brien</LastName><ForeName>Emmanuelle</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Equipe Région INSERM ERI 24, Groupe de Recherche sur l'Alcool et les Pharmacodépendances, Université de Picardie Jules Verne, Faculté de Pharmacie, Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Legastelois</LastName><ForeName>Rémi</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Houchi</LastName><ForeName>Hakim</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Vilpoux</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Alaux-Cantin</LastName><ForeName>Stéphanie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Pierrefiche</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>André</LastName><ForeName>Etienne</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Naassila</LastName><ForeName>Mickaël</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropsychopharmacology</MedlineTA><NlmUniqueID>8904907</NlmUniqueID><ISSNLinking>0893-133X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002492">Central Nervous System Depressants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003521">Cyclopropanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>01K63SUP8D</RegistryNumber><NameOfSubstance UI="D005473">Fluoxetine</NameOfSubstance></Chemical><Chemical><RegistryNumber>3K9958V90M</RegistryNumber><NameOfSubstance UI="D000431">Ethanol</NameOfSubstance></Chemical><Chemical><RegistryNumber>G56VK1HF36</RegistryNumber><NameOfSubstance UI="D000078764">Milnacipran</NameOfSubstance></Chemical><Chemical><RegistryNumber>TG537D343B</RegistryNumber><NameOfSubstance UI="D003891">Desipramine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002492" MajorTopicYN="N">Central Nervous System Depressants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003216" MajorTopicYN="N">Conditioning, Operant</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003521" MajorTopicYN="N">Cyclopropanes</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003891" MajorTopicYN="N">Desipramine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000431" MajorTopicYN="N">Ethanol</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005108" MajorTopicYN="N">Extinction, Psychological</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005473" MajorTopicYN="N">Fluoxetine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008124" MajorTopicYN="N">Locomotion</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008811" MajorTopicYN="N">Mice, Inbred DBA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078764" MajorTopicYN="N">Milnacipran</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012646" MajorTopicYN="N">Self Administration</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21430652</ArticleId><ArticleId IdType="pii">npp201137</ArticleId><ArticleId IdType="doi">10.1038/npp.2011.37</ArticleId><ArticleId IdType="pmc">PMC3096819</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neuropsychopharmacology. 2000 Jun;22(6):581-94</Citation><ArticleIdList><ArticleId IdType="pubmed">10788758</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2000 May;24(5):588-94</Citation><ArticleIdList><ArticleId IdType="pubmed">10832899</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2000;14(4):340-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11198050</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1984;84(4):466-75</Citation><ArticleIdList><ArticleId IdType="pubmed">6441946</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jan;29(1):55-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15610945</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 1995 Apr;19(2):269-78</Citation><ArticleIdList><ArticleId IdType="pubmed">7625557</ArticleId></ArticleIdList></Reference><Reference><Citation>Horm Behav. 1994 Sep;28(3):241-60</Citation><ArticleIdList><ArticleId IdType="pubmed">7814005</ArticleId></ArticleIdList></Reference><Reference><Citation>Synapse. 1990;5(1):48-58</Citation><ArticleIdList><ArticleId IdType="pubmed">2300906</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2004 Nov;28(11):1676-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15547454</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2008 Dec;201(2):249-60</Citation><ArticleIdList><ArticleId IdType="pubmed">18685830</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 1998 Aug;46(6):547-54</Citation><ArticleIdList><ArticleId IdType="pubmed">9744293</ArticleId></ArticleIdList></Reference><Reference><Citation>Recent Dev Alcohol. 1989;7:255-66</Citation><ArticleIdList><ArticleId IdType="pubmed">2522667</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2002 Nov;303(2):664-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12388649</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Protoc Neurosci. 2008 Jul;Chapter 9:Unit 9.29</Citation><ArticleIdList><ArticleId IdType="pubmed">18634001</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2005 Dec 28;528(1-3):103-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16325805</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Pharmacol. 2008 Feb;19(1):1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">18195589</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2010 Oct;212(3):431-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20676608</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2001;62 Suppl 20:26-31</Citation><ArticleIdList><ArticleId IdType="pubmed">11584872</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 1997 Jul;18(7):229-31</Citation><ArticleIdList><ArticleId IdType="pubmed">9253852</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Genet. 2003 May;33(3):311-24</Citation><ArticleIdList><ArticleId IdType="pubmed">12837020</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 1986 Aug;10(4):436-42</Citation><ArticleIdList><ArticleId IdType="pubmed">3530023</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Biochem Behav. 2005 Oct;82(2):388-96</Citation><ArticleIdList><ArticleId IdType="pubmed">16219342</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2006 Sep 30;30(7):1196-201</Citation><ArticleIdList><ArticleId IdType="pubmed">16624467</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol. 1985 Mar-Apr;2(2):349-52</Citation><ArticleIdList><ArticleId IdType="pubmed">3925968</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 1991 Sep-Dec;16(3):223-44</Citation><ArticleIdList><ArticleId IdType="pubmed">1665095</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 1999 Apr 16;370(3):217-23</Citation><ArticleIdList><ArticleId IdType="pubmed">10334495</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Biochem Behav. 2002 May;72(1-2):483-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11900823</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1994 Sep 15;36(6):395-421</Citation><ArticleIdList><ArticleId IdType="pubmed">7803601</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2008 Jun;33(7):1724-34</Citation><ArticleIdList><ArticleId IdType="pubmed">17805311</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Biochem Behav. 2010 Jan;94(3):431-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19879891</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol. 1998 Oct;16(3):249-70</Citation><ArticleIdList><ArticleId IdType="pubmed">9744857</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Today (Barc). 2008 Sep;44(9):653-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19137120</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 1995 Sep;116(2):1923-31</Citation><ArticleIdList><ArticleId IdType="pubmed">8528581</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2002 Jul;162(3):323-32</Citation><ArticleIdList><ArticleId IdType="pubmed">12122491</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2008 Oct;55(5):803-11</Citation><ArticleIdList><ArticleId IdType="pubmed">18625256</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol. 1984 Sep-Oct;1(5):379-83</Citation><ArticleIdList><ArticleId IdType="pubmed">6152651</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2005 May;179(2):366-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15551068</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol. 2008 Mar;42(2):91-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18358987</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Physiol Pharmacol. 1975 Apr;53(2):248-55</Citation><ArticleIdList><ArticleId IdType="pubmed">165867</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 1992 Feb;13(2):69-75</Citation><ArticleIdList><ArticleId IdType="pubmed">1561716</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 1998 Mar;18(3):135-74</Citation><ArticleIdList><ArticleId IdType="pubmed">9471114</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Des. 2010;16(19):2126-35</Citation><ArticleIdList><ArticleId IdType="pubmed">20482508</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2001 May 25;69(1):37-46</Citation><ArticleIdList><ArticleId IdType="pubmed">11411809</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2002 Oct;26(10):1494-501</Citation><ArticleIdList><ArticleId IdType="pubmed">12394282</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Pharmacol. 2009 Feb;20(1):78-83</Citation><ArticleIdList><ArticleId IdType="pubmed">19106764</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2009 Jul 15;66(2):146-53</Citation><ArticleIdList><ArticleId IdType="pubmed">19232578</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 1997;61(16):PL 235-42</Citation><ArticleIdList><ArticleId IdType="pubmed">9353173</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2006 Nov 27;17(17):1813-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17164670</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1998 Feb;135(4):374-82</Citation><ArticleIdList><ArticleId IdType="pubmed">9539262</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 1999 Sep;21(3):435-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10457541</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Alcohol. 1996 Mar;31 Suppl 1:27-32</Citation><ArticleIdList><ArticleId IdType="pubmed">8736998</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1994 Dec;151(12):1723-34</Citation><ArticleIdList><ArticleId IdType="pubmed">7977877</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2005 Oct;29(10):1759-68</Citation><ArticleIdList><ArticleId IdType="pubmed">16269905</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2006 Jul;31(7):1489-99</Citation><ArticleIdList><ArticleId IdType="pubmed">16237389</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Biochem Behav. 2000 Nov;67(3):629-36</Citation><ArticleIdList><ArticleId IdType="pubmed">11164095</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Exp Med Biol. 1977;85A:515-38</Citation><ArticleIdList><ArticleId IdType="pubmed">200119</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2008 Dec;55(7):1199-211</Citation><ArticleIdList><ArticleId IdType="pubmed">18713641</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2002 Jan;16(1):27-35</Citation><ArticleIdList><ArticleId IdType="pubmed">11772933</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2002 Jun 28;71(6):707-15</Citation><ArticleIdList><ArticleId IdType="pubmed">12072158</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Today (Barc). 1998 Aug;34(8):709-20</Citation><ArticleIdList><ArticleId IdType="pubmed">14988777</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Alcohol. 2003 May-Jun;38(3):224-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12711656</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2007 Jul;32(7):1433-51</Citation><ArticleIdList><ArticleId IdType="pubmed">17164822</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2004 Mar 4;357(2):91-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15036582</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Biochem Behav. 2008 Feb;88(4):456-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17988724</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Pharmacol. 2001 Nov;12(6-7):535-43</Citation><ArticleIdList><ArticleId IdType="pubmed">11742148</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91</Citation><ArticleIdList><ArticleId IdType="pubmed">8401595</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2007 Mar 7;27(10):2718-26</Citation><ArticleIdList><ArticleId IdType="pubmed">17344409</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 Nov;155(11):1544-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9812115</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1996 Sep;127(2):83-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8888371</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2007 Nov;31(11):1866-71</Citation><ArticleIdList><ArticleId IdType="pubmed">17908267</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001712 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001712 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= AutomedicationFrancoV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:21430652
|texte= Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent rats.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:21430652" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AutomedicationFrancoV1
| This area was generated with Dilib version V0.6.38. |  |